133 related articles for article (PubMed ID: 34375561)
1. Effect of Clinical Trial Participation on Costs to Payers in Metastatic Non-Small-Cell Lung Cancer.
Merkhofer C; Chennupati S; Sun Q; Eaton KD; Martins RG; Ramsey SD; Goulart BHL
JCO Oncol Pract; 2021 Aug; 17(8):e1225-e1234. PubMed ID: 34375561
[TBL] [Abstract][Full Text] [Related]
2. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
[TBL] [Abstract][Full Text] [Related]
3. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
4. Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study.
Hess LM; Michael D; Krein PM; Marquart T; Sireci AN
J Med Econ; 2023; 26(1):43-50. PubMed ID: 36453626
[TBL] [Abstract][Full Text] [Related]
5. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
6. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
7. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
[TBL] [Abstract][Full Text] [Related]
8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
George S; Bell EJ; Zheng Y; Kim R; White J; Devgan G; Smith J; Lal LS; Engel-Nitz NM; Liu FX
Oncologist; 2021 Jul; 26(7):e1205-e1215. PubMed ID: 33955118
[TBL] [Abstract][Full Text] [Related]
10. Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.
Merkhofer CM; Eaton KD; Martins RG; Ramsey SD; Goulart BHL
Clin Lung Cancer; 2021 Nov; 22(6):523-530. PubMed ID: 34059474
[TBL] [Abstract][Full Text] [Related]
11. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
[TBL] [Abstract][Full Text] [Related]
12. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
13. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
Nesline MK; Knight T; Colman S; Patel K
Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
[TBL] [Abstract][Full Text] [Related]
14. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
15. Actuarial analysis of private payer administrative claims data for women with endometriosis.
Mirkin D; Murphy-Barron C; Iwasaki K
J Manag Care Pharm; 2007 Apr; 13(3):262-72. PubMed ID: 17407392
[TBL] [Abstract][Full Text] [Related]
16. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
17. Hospital Variation in Spending for Lung Cancer Resection in Medicare Beneficiaries.
Jean RA; Bongiovanni T; Soulos PR; Chiu AS; Herrin J; Kim N; Xu X; Kim AW; Gross CP
Ann Thorac Surg; 2019 Dec; 108(6):1710-1716. PubMed ID: 31400321
[TBL] [Abstract][Full Text] [Related]
18. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
19. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
Kwan SW; Mortell KE; Hippe DS; Brunner MC
J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
[TBL] [Abstract][Full Text] [Related]
20. Budget Impact Analysis to Estimate the Cost Dynamics of Treating Refractory Gastroesophageal Reflux Disease With Radiofrequency Energy: a Payer Perspective.
Gregory D; Scotti DJ; Buck D; Triadafilopoulos G
Manag Care; 2016 May; 25(5):42-50. PubMed ID: 27348962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
